Ad-hoc | 9 December 2010 16:19
STRATEC Biomedical Systems AG / Key word(s): Change of Personnel
09.12.2010 16:19
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
STRATEC appoints new CEO, effective April 1, 2011
Birkenfeld, December 9, 2010
STRATEC Biomedical Systems AG, Birkenfeld, Germany, (Frankfurt: SBS; Prime
Standard; TecDAX) today announces the planned transition of its senior
management team. The company's Supervisory Board has resolved to appoint
Marcus Wolfinger, currently CFO and a member of the Board of Management for
eleven years, to the positions of Chairman of the Board of Management and
CEO effective April 1, 2011.
This transition, along with a restructuring of the Board of Management, is
due to the decision taken by Hermann Leistner, the founder, current
Chairman of the Board of Management and CEO of STRATEC, to retire from his
position on March 31, 2011 and to conclude his active professional career
after more than 30 years at STRATEC. Hermann Leistner will remain
associated with STRATEC in an advisory capacity. Bernd Steidle, member of
the Board of Management since August 2000, will remain responsible for
Sales and Marketing.
The Board of Management of STRATEC will be augmented from February 1, 2011
by the appointment of Dr. Robert Siegle, who currently holds the position
of Deputy Chairman of the Supervisory Board. He will be responsible for
Human Resources, Compliance and Legal Affairs as well as coordinating the
activities of STRATEC's subsidiaries. Dr. Siegle has played an active role
in shaping STRATEC's development as a member of its Supervisory Board since
1998. During this tenure on the Supervisory Board Dr. Siegle oversaw the
company's legal and contractual relationships with its customers.
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
Fred K. Brückner, Chairman of STRATEC's Supervisory Board, commented: 'Over
the past 30 years, Hermann Leistner has built a company that plays a major
role as an innovative and reliable partner to many leading global
diagnostics companies. STRATEC also offers an attractive and motivating
working environment to more than 450 people, not only in the company's home
region but across its global locations. This profile was made possible in
large part by Hermann Leistner through great personal commitment and his
clear vision. By establishing a growth-oriented company structure, he and
his management team have laid the foundations that place STRATEC on a solid
footing for the long term. Hermann Leistner has now decided to reduce his
professional activities to an advisory function at STRATEC and to focus on
his private life. Whilst we are sad to see him leave the Board of
Management, we are in the fortunate position of having the right successor
in Marcus Wolfinger as a ready-made replacement and someone who can
guarantee continuity in the successful management of the company. Marcus
Wolfinger has been with STRATEC since 1998 and a member of its Board of
Management since 1999. During this time, he has increasingly been involved
in the company's strategic alignment, delivering both exceptional business
performance and its independent, solid financial development. I am
convinced that in him we have the right person to lead STRATEC through the
next stage in its development. The roles played by
Marcus Wolfinger and Bernd Steidle over the past ten years, and the future
structure of the new management team alongside Dr. Robert Siegle, will mean
that we can guarantee the key success factors in our industry - continuity
and reliability - going forward.'
Marcus Wolfinger, CEO-elect of STRATEC Biomedical Systems AG, added: 'I
look forward to accepting the challenge presented by the roles of CEO and
Chairman of the Board of Management. On behalf of the entire STRATEC team,
I would like to thank Hermann Leistner for building up the STRATEC Group
from its foundation to what it is now - a global market leader. We are on
the threshold of a further period of dynamic growth, an achievement chiefly
due to Hermann Leistner's efforts. STRATEC remains on a clear growth course
in terms of both its strategy and its business performance. Our employees,
shareholders and customers can expect the same keen focus and commitment
from the STRATEC team, but with invigorated leadership and drive.'
The Leistner family remains committed to its position as STRATEC's
principal shareholder and has no intention of changing that fact. Hermann
Leistner, his family and his investment company currently own more than 43%
of STRATEC's share capital. Although Hermann Leistner has expressed no
intention of joining the company's Supervisory Board, he will continue to
accompany the company in an advisory capacity, specifically as head of the
STRATEC Technology Scouting Committee, a group of internal and external
experts.
About STRATEC
STRATEC Biomedical Systems AG (www.stratec-biomedical.de) designs and
manufactures fully automated systems for its partners in the fields of
clinical diagnostics and biotechnology. These partners market such systems,
in general together with their own reagents, to laboratories, blood banks
and research institutes around the world. The company develops its products
on the basis of its own patented technologies. Shares in the company (ISIN:
DE0007289001) are traded in the Prime Standard segment of the Frankfurt
Stock Exchange, and are a constituent of the Deutsche Börse TecDAX.
The STRATEC Group consists of the publicly listed parent company STRATEC
Biomedical Systems AG and of subsidiaries and second-tier subsidiaries in
Germany, the USA, the UK, Switzerland and Romania.
Further information can be obtained from:
STRATEC Biomedical Systems AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Phone: +49 7082 7916 190
Fax: +49 7082 7916 999
ir@stratec-biomedical.de
www.stratec-biomedical.de
09.12.2010 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: STRATEC Biomedical Systems AG
Gewerbestraße 37
75217 Birkenfeld
Deutschland
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec-biomedical.de
Internet: www.stratec-biomedical.de
ISIN: DE0007289001
WKN: 728900
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------